Country: Canada
Language: English
Source: Health Canada
BACLOFEN
LABORATOIRE RIVA INC.
M03BX01
BACLOFEN
10MG
TABLET
BACLOFEN 10MG
ORAL
100/500
Prescription
GABA-DERIVATIVE SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0113246001; AHFS:
APPROVED
2000-04-20
_RIVA-BACLOFEN - Product Monograph _ _Page 1 of 23 _ PRODUCT MONOGRAPH PR RIVA-BACLOFEN Baclofen Tablets, USP 10 mg and 20 mg ANTISPASTIC AGENT LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com DATE OF REVISION: February 5, 2021 Submission Control No.: 248258 _RIVA-BACLOFEN - Product Monograph _ _Page 2 of 23 _ PR RIVA-BACLOFEN Baclofen Tablets, USP 10 mg and 20 mg THERAPEUTIC CLASSIFICATION Antispastic Agent ACTION AND CLINICAL PHARMACOLOGY MECHANISM OF ACTION (MOA) The precise mechanisms of action of baclofen are not fully known. It inhibits both monosynaptic and polysynaptic reflexes at the spinal level, probably by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. Peak plasma concentrations of baclofen are achieved within 2 hours and the plasma half-life is 2 – 4 hours. _SPECIAL POPULATIONS _ GERIATRICS (AGED 65 YEARS OR ABOVE) Following a single oral dose, elderly patients have a slower rate of absorption and elimination, a slightly prolonged elimination half-life, but a similar systemic exposure of baclofen compared to young adults. HEPATIC IMPAIRMENT No pharmacokinetic data is available in patients with hepatic impairment after administration of baclofen. However, as the liver does not play a significant role in the disposition of baclofen, it is unlikely that baclofen pharmacokinetics would be altered to a clinically significant level in patients with hepatic impairment. RENAL IMPAIRMENT No controlled clinical pharmacokinetic study is available in patients with renal impairment after administration of baclofen. Baclofen is predominantly eliminated unchanged in urine. Sparse plasma concentration data collected in female patients under chronic hemodialysis or compensat Read the complete document